Regeneron (REGN) Pharmaceuticals announced updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran combination treatment against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results